Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pijus Mandal

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
The Journal of Biological Chemistry|May 10, 2018
Small molecule targeting of the STAT5/6 Src homology 2 (SH2) domains to inhibit allergic airway diseaseJ Morgan Knight, Pijus Mandal, Pietro Morlacchi, et al.
ACS Medicinal Chemistry Letters|February 18, 2026
Structure-Guided Development of NRAS G12D Inhibitors Based on a 5‑Azaindole CoreJoshua B Cox, Vinay Nair, Pijus Mandal, et al.
Journal of Medicinal Chemistry|October 13, 2021
Discovery of 6-[(3<i>S</i>,4<i>S</i>)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 InhibitorBarbara Czako, Yuting Sun, Timothy McAfoos, et al.
Journal of Medicinal Chemistry|August 14, 2020
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1RBarbara Czako, Joseph R Marszalek, Jason P Burke, et al.
Nature Metabolism|November 24, 2020
An enolase inhibitor for the targeted treatment of ENO1-deleted cancersYu-Hsi Lin, Nikunj Satani, Naima Hammoudi, et al.
Nature Metabolism|December 19, 2020
Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancersYu-Hsi Lin, Nikunj Satani, Naima Hammoudi, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The Journal of Biological Chemistry|May 10, 2018
Small molecule targeting of the STAT5/6 Src homology 2 (SH2) domains to inhibit allergic airway diseaseJ Morgan Knight, Pijus Mandal, Pietro Morlacchi, et al.
ACS Medicinal Chemistry Letters|February 18, 2026
Structure-Guided Development of NRAS G12D Inhibitors Based on a 5‑Azaindole CoreJoshua B Cox, Vinay Nair, Pijus Mandal, et al.
Journal of Medicinal Chemistry|October 13, 2021
Discovery of 6-[(3<i>S</i>,4<i>S</i>)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 InhibitorBarbara Czako, Yuting Sun, Timothy McAfoos, et al.
Journal of Medicinal Chemistry|August 14, 2020
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1RBarbara Czako, Joseph R Marszalek, Jason P Burke, et al.
Nature Metabolism|November 24, 2020
An enolase inhibitor for the targeted treatment of ENO1-deleted cancersYu-Hsi Lin, Nikunj Satani, Naima Hammoudi, et al.
Nature Metabolism|December 19, 2020
Author Correction: An enolase inhibitor for the targeted treatment of ENO1-deleted cancersYu-Hsi Lin, Nikunj Satani, Naima Hammoudi, et al.
Pageof 1